(Total Views: 610)
Posted On: 09/29/2022 2:12:03 PM
Post# of 148887
I decided to wait a day before i post my opinion of the CC. I for the most part am disappointed with it. I don't have a problem with any of the talented reputable people running the company, i am disappointed with the hard reset attitude about the company. It is as if Nader and Amarex are gone so now we have to start over. I feel this is a very wrong attitude and this team has had a few months to evaluate the situation and by now action and results should be taking place. I honestly feel it was not crazy for many of us to be optimistic there was more progress on the BLA and that the clinical hold has been lifted.
The truth is the drug is the same, the market is the same and the need is the same. Cyrus may be new, but to re-evaluate the value of indications and focus the company is something that should have been done in the first few weeks of his employment. Many on this forum can tell Cyrus the market value in every indication in a few minuets.
We are all by now long term investors that are still left wondering what the real scope of work is needed to get he BLA done. The trial for HIV combo was done in 2018. we had a share count of 375 million. we are now 4 years down the road and 1.2 billion shares. The HIV trial did not take as long or require nearly the # of shares as getting the BLA done. They can blame Amarex all they want, but until they sue them it is just excuses. At this point they have had the data to finish it off long enough to have a timeline at least.
However, I have to take a step back and look at what Cytodyn's role really is. They are not going to become a pharma selling their drug. That leaves partnership with a pharma and/or a buyout. the future partner/owner is investing in Leronlimab and leronlimab only. Cytodyn only has to show the data in trials that are as close to an FDA trial as possible to erase all doubt about Leronlimab's ability to get approved and it's market size capability. That is all they need to do for Nash and Cancer. the cost in time and money for FDA approval will be on the partner/new owner. HIV, is too far along to not get FDA approval and is a huge part of assuring the future partner that this drug is for real.
I am furious about Dr. Kelly's answer about right to try. Nader may have screwed up the company in many ways but he has compassion for the patients and knows he must help where he can. If cytodyn cannot participate in right to try for some other reason than it is so much work, they need to be honest about it. People need the drug yesterday and cytodyn blew it with covid and is still blowing it with HIV. If Cyrus wants to assure things are better now, get HIV done now.
The truth is the drug is the same, the market is the same and the need is the same. Cyrus may be new, but to re-evaluate the value of indications and focus the company is something that should have been done in the first few weeks of his employment. Many on this forum can tell Cyrus the market value in every indication in a few minuets.
We are all by now long term investors that are still left wondering what the real scope of work is needed to get he BLA done. The trial for HIV combo was done in 2018. we had a share count of 375 million. we are now 4 years down the road and 1.2 billion shares. The HIV trial did not take as long or require nearly the # of shares as getting the BLA done. They can blame Amarex all they want, but until they sue them it is just excuses. At this point they have had the data to finish it off long enough to have a timeline at least.
However, I have to take a step back and look at what Cytodyn's role really is. They are not going to become a pharma selling their drug. That leaves partnership with a pharma and/or a buyout. the future partner/owner is investing in Leronlimab and leronlimab only. Cytodyn only has to show the data in trials that are as close to an FDA trial as possible to erase all doubt about Leronlimab's ability to get approved and it's market size capability. That is all they need to do for Nash and Cancer. the cost in time and money for FDA approval will be on the partner/new owner. HIV, is too far along to not get FDA approval and is a huge part of assuring the future partner that this drug is for real.
I am furious about Dr. Kelly's answer about right to try. Nader may have screwed up the company in many ways but he has compassion for the patients and knows he must help where he can. If cytodyn cannot participate in right to try for some other reason than it is so much work, they need to be honest about it. People need the drug yesterday and cytodyn blew it with covid and is still blowing it with HIV. If Cyrus wants to assure things are better now, get HIV done now.
(21)
(0)Scroll down for more posts ▼
